ZA200900019B - Tyrosine kinase inhibitors - Google Patents
Tyrosine kinase inhibitorsInfo
- Publication number
- ZA200900019B ZA200900019B ZA200900019A ZA200900019A ZA200900019B ZA 200900019 B ZA200900019 B ZA 200900019B ZA 200900019 A ZA200900019 A ZA 200900019A ZA 200900019 A ZA200900019 A ZA 200900019A ZA 200900019 B ZA200900019 B ZA 200900019B
- Authority
- ZA
- South Africa
- Prior art keywords
- tyrosine kinase
- kinase inhibitors
- inhibitors
- tyrosine
- kinase
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
- C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
- C07D221/04—Ortho- or peri-condensed ring systems
- C07D221/06—Ring systems of three rings
- C07D221/16—Ring systems of three rings containing carbocyclic rings other than six-membered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Oncology (AREA)
- Heart & Thoracic Surgery (AREA)
- Epidemiology (AREA)
- Cardiology (AREA)
- Hematology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Ophthalmology & Optometry (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
- Pyridine Compounds (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US81976406P | 2006-07-10 | 2006-07-10 |
Publications (1)
Publication Number | Publication Date |
---|---|
ZA200900019B true ZA200900019B (en) | 2009-11-25 |
Family
ID=38923821
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ZA200900019A ZA200900019B (en) | 2006-07-10 | 2009-01-05 | Tyrosine kinase inhibitors |
Country Status (24)
Country | Link |
---|---|
US (2) | US8222269B2 (xx) |
EP (1) | EP2049494B1 (xx) |
JP (2) | JP4203121B1 (xx) |
KR (1) | KR20090026187A (xx) |
CN (1) | CN101535268B (xx) |
AR (1) | AR061804A1 (xx) |
AU (1) | AU2007273081B2 (xx) |
BR (1) | BRPI0713941A2 (xx) |
CA (1) | CA2656578C (xx) |
CO (1) | CO6190518A2 (xx) |
CR (1) | CR10560A (xx) |
EC (1) | ECSP099051A (xx) |
ES (1) | ES2497493T3 (xx) |
GT (1) | GT200900004A (xx) |
HN (1) | HN2009000018A (xx) |
IL (1) | IL196337A0 (xx) |
MA (1) | MA30631B1 (xx) |
MX (1) | MX2009000410A (xx) |
NO (1) | NO20090608L (xx) |
PE (1) | PE20080275A1 (xx) |
RU (1) | RU2009104303A (xx) |
TW (1) | TW200813021A (xx) |
WO (1) | WO2008008310A2 (xx) |
ZA (1) | ZA200900019B (xx) |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP4119478B1 (ja) | 2005-06-23 | 2008-07-16 | メルク エンド カムパニー インコーポレーテッド | チロシンキナーゼインヒビター |
US7893081B2 (en) | 2007-12-20 | 2011-02-22 | Merck & Co., Inc. | Tyrosine kinase inhibitors |
CN102036560A (zh) * | 2008-05-21 | 2011-04-27 | 巴斯夫欧洲公司 | 取代吡啶-4-基甲基磺酰胺 |
WO2011041157A1 (en) * | 2009-09-30 | 2011-04-07 | Merck Sharp & Dohme Corp. | Crystalline hydrochloride salts of c-met kinase inhibitors |
CA2772127A1 (en) * | 2009-09-30 | 2011-04-07 | Merck Sharp & Dohme Ltd | Formulations for c-met kinase inhibitors |
NZ703111A (en) | 2010-05-17 | 2016-07-29 | Incozen Therapeutics Pvt Ltd | Novel 3,5-disubstitued-3h-imidazo[4,5-b]pyridine and 3,5- disubstitued -3h-[1,2,3]triazolo[4,5-b] pyridine compounds as modulators of protein kinases |
US20130315895A1 (en) | 2010-07-01 | 2013-11-28 | Takeda Pharmaceutical Company Limited | COMBINATION OF A cMET INHIBITOR AND AN ANTIBODY TO HGF AND/OR cMET |
WO2013144737A2 (en) | 2012-03-30 | 2013-10-03 | Rhizen Pharmaceuticals Sa | Novel 3,5-disubstitued-3h-imidazo[4,5-b]pyridine and 3,5- disubstitued -3h-[1,2,3]triazolo[4,5-b] pyridine compounds as modulators of c-met protein kinases |
CN104797267A (zh) | 2012-06-26 | 2015-07-22 | 德玛医药 | 使用卫康醇、二乙酰二脱水卫矛醇、二溴卫矛醇或类似物或其衍生物治疗具有基因多型性或ahi1失调或突变患者的抗酪氨酸激酶抑制剂的恶性肿瘤的方法 |
JP2016519684A (ja) | 2013-04-08 | 2016-07-07 | デニス エム ブラウン | 準最適に投与された薬物療法の有効性を改善するための及び/又は副作用を低減するための方法および組成物 |
WO2015017528A1 (en) * | 2013-07-30 | 2015-02-05 | Blueprint Medicines Corporation | Pik3c2g fusions |
US10407509B2 (en) | 2013-07-30 | 2019-09-10 | Blueprint Medicines Corporation | NTRK2 fusions |
ES2764299T3 (es) | 2014-12-09 | 2020-06-02 | Inst Nat Sante Rech Med | Anticuerpos monoclonales humanos contra AXL |
WO2016135041A1 (en) | 2015-02-26 | 2016-09-01 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Fusion proteins and antibodies comprising thereof for promoting apoptosis |
CN109562102A (zh) * | 2016-06-17 | 2019-04-02 | 宾夕法尼亚大学董事会 | 用于预防和/或治疗癌症的化合物、组合物和方法 |
AU2020242287A1 (en) | 2019-03-21 | 2021-09-02 | INSERM (Institut National de la Santé et de la Recherche Médicale) | A Dbait molecule in combination with kinase inhibitor for the treatment of cancer |
WO2021089791A1 (en) | 2019-11-08 | 2021-05-14 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for the treatment of cancers that have acquired resistance to kinase inhibitors |
WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NL132137C (xx) | 1963-04-24 | |||
US4826853A (en) | 1986-10-31 | 1989-05-02 | Schering Corporation | 6,11-Dihydro-11-(N-substituted-4-piperidylidene)-5H-benzo(5,6)cyclohepta(1,2-B)pyridines and compositions and methods of use |
JP2852659B2 (ja) | 1988-03-03 | 1999-02-03 | 富山化学工業株式会社 | ピペラジン誘導体およびその塩 |
NZ238629A (en) | 1990-06-22 | 1993-09-27 | Schering Corp | Bis-benzo- or benzopyrido-cyclohepta (where z is c, o, s or n) piperidine, piperidylidene or piperazine compounds, medicaments and methods of preparation |
US6365588B1 (en) | 1993-10-15 | 2002-04-02 | Schering Corporation | Tricyclic amide and urea compounds useful for inhibition of G-protein function and for treatment of proliferative diseases |
JP3847786B2 (ja) | 1995-10-16 | 2006-11-22 | 協和醗酵工業株式会社 | 三環性化合物 |
CZ83499A3 (cs) | 1996-09-13 | 1999-07-14 | Schering Corporation | Tricyklické sloučeniny, farmaceutický prostředek je obsahující a jejich použití |
DE69733142T2 (de) | 1996-09-13 | 2006-03-16 | Schering Corp. | Substituierte benzocycloheptapyridine derivate verwendbar als farnesyl-protein transferase inhibitoren |
MXPA04002682A (es) | 2001-09-19 | 2004-06-18 | Pharmacia Corp | Compuestos pirazolilo sustituidos para el tratamiento de la inflamacion. |
WO2003084931A1 (en) | 2002-04-02 | 2003-10-16 | Merck & Co., Inc. | 5h-benzo[4,5]cyclohepta[1,2-b]pyridine nmda/nr2b antagonists |
GB0211649D0 (en) * | 2002-05-21 | 2002-07-03 | Novartis Ag | Organic compounds |
ES2211315B1 (es) | 2002-11-12 | 2005-10-16 | Almirall Prodesfarma, S.A. | Nuevos compuestos triciclicos. |
JP2006151809A (ja) | 2002-12-26 | 2006-06-15 | Ube Ind Ltd | ベンゾシクロヘプタピリジン化合物 |
US20060025406A1 (en) * | 2004-07-06 | 2006-02-02 | Angion Biomedica Corporation | Modulators of hepatocyte growth factor/c- Met activity |
JP4119478B1 (ja) | 2005-06-23 | 2008-07-16 | メルク エンド カムパニー インコーポレーテッド | チロシンキナーゼインヒビター |
TW200738638A (en) | 2005-06-23 | 2007-10-16 | Merck & Co Inc | Tyrosine kinase inhibitors |
-
2007
- 2007-07-02 TW TW096124020A patent/TW200813021A/zh unknown
- 2007-07-03 AR ARP070102972A patent/AR061804A1/es not_active Application Discontinuation
- 2007-07-05 PE PE2007000877A patent/PE20080275A1/es not_active Application Discontinuation
- 2007-07-06 BR BRPI0713941-1A patent/BRPI0713941A2/pt not_active Application Discontinuation
- 2007-07-06 EP EP07810282.9A patent/EP2049494B1/en active Active
- 2007-07-06 WO PCT/US2007/015675 patent/WO2008008310A2/en active Application Filing
- 2007-07-06 RU RU2009104303/04A patent/RU2009104303A/ru not_active Application Discontinuation
- 2007-07-06 AU AU2007273081A patent/AU2007273081B2/en active Active
- 2007-07-06 CN CN2007800335075A patent/CN101535268B/zh active Active
- 2007-07-06 JP JP2008536664A patent/JP4203121B1/ja active Active
- 2007-07-06 MX MX2009000410A patent/MX2009000410A/es not_active Application Discontinuation
- 2007-07-06 ES ES07810282.9T patent/ES2497493T3/es active Active
- 2007-07-06 CA CA2656578A patent/CA2656578C/en active Active
- 2007-07-06 US US12/309,149 patent/US8222269B2/en active Active
- 2007-07-06 KR KR1020097000538A patent/KR20090026187A/ko not_active Application Discontinuation
- 2007-07-09 US US11/827,109 patent/US8101603B2/en active Active
-
2008
- 2008-04-21 JP JP2008109902A patent/JP5245045B2/ja active Active
-
2009
- 2009-01-01 IL IL196337A patent/IL196337A0/en unknown
- 2009-01-05 ZA ZA200900019A patent/ZA200900019B/xx unknown
- 2009-01-06 CO CO09000744A patent/CO6190518A2/es not_active Application Discontinuation
- 2009-01-07 HN HN2009000018A patent/HN2009000018A/es unknown
- 2009-01-09 EC EC2009009051A patent/ECSP099051A/es unknown
- 2009-01-09 GT GT200900004A patent/GT200900004A/es unknown
- 2009-01-14 CR CR10560A patent/CR10560A/es not_active Application Discontinuation
- 2009-02-09 NO NO20090608A patent/NO20090608L/no not_active Application Discontinuation
- 2009-02-09 MA MA31620A patent/MA30631B1/fr unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HUS2200052I1 (hu) | Imidazotriazinok és imidazopirimidinek mint kinázgátlók | |
EP2040546A4 (en) | TYROSINE KINASE INHIBITORS | |
ZA200900019B (en) | Tyrosine kinase inhibitors | |
IL197381A0 (en) | Kinase inhibitor | |
IL190078A0 (en) | Kinase inhibitors | |
HK1114380A1 (en) | Pyrrolopyrazoles as kinase inhibitors | |
PL2041138T3 (pl) | Pirolotriazyny jako inhibitory kinazy | |
IL193482A0 (en) | Hydantoin based kinase inhibitors | |
PL1943243T3 (pl) | Inhibitory kinazy | |
PL1896422T3 (pl) | Inhibitory kinazy tyrozynowej | |
EP2247185A4 (en) | INHIBITORS OF TYROSINE KINASE | |
EP2036893A4 (en) | ABL Kinase Inhibitor | |
EP1951252A4 (en) | INHIBITORS OF TYROSINE KINASES | |
ZA200908943B (en) | Pyrazolopyrimidinone kinase inhibitor | |
IL197981A0 (en) | Kinase inhibitors | |
ZA200810573B (en) | Substituted 3-cyanopyridines as protein kinase inhibitors | |
ZA200806993B (en) | Hydantoin based kinase inhibitors | |
GB0621719D0 (en) | Ikk- serine-threonine protein kinase inhibitors | |
IL189985A0 (en) | Kinase inhibitors | |
ZA200803287B (en) | Kinase inhibitors | |
GB0715470D0 (en) | IKK- serine-threonine protein kinase inhibitors |